Antibody-drug conjugates comprising anti-etb-r antibodies and uses thereof

By optimizing the composition of the anti-ETB-R antibody-drug conjugate, the problems of high toxicity and poor pharmacokinetics of existing ADCs when targeting cancer cells were solved, achieving high concentrations of drug accumulation in tumor cells and improving the safety and efficacy of cancer treatment.

CN122249238APending Publication Date: 2026-06-19SAIMAI BIOTHERAPEUTICS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SAIMAI BIOTHERAPEUTICS
Filing Date
2024-11-26
Publication Date
2026-06-19

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates generally to the medical field. More specifically, it relates to novel antibody-drug conjugates and their uses.
Need to check novelty before this filing date? Find Prior Art